Background. Daclatasvir (DCV) is a potent hepatitis C virus (HCV) NS5A replication complex inhibitor with pangenotypic (GT 1-6) activity in vitro. Asunaprevir (ASV) is a selective NS3 protease inhibitor with in vitro activity against GT 1, 4, 5 and 6. These two direct-acting antivirals (DAA) are in phase 3 development and regulatory review as a dual-DAA regimen (DCV + ASV) for the treatment of HCV GT 1b. DCV and ASV both inhibit P-glycoprotein (P-gp) and individually increase plasma concentrations of the P-gp substrate digoxin (DIG), increasing DIG C max by 65 and 9% and AUC TAU by 27 and 30%, respectively. The combined effect of DCV + ASV on the pharmacokinetics (PK) of DIG was therefore assessed in healthy subjects.
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Methods. A single sequence, open-label, one-way interaction study assessed the effect of steady-state DCV (60 mg QD) plus ASV (100 mg BID [softgel capsule]) on the PK of single-dose 0.25 mg DIG in healthy subjects. Subjects (N = 16) received DIG on Day 1 and 16, and DCV + ASV on Days 6-20. Serial samples for DIG plasma concentrations were collected up to 120 h postdose on Day 1 and Day 16. Non-compartmental DIG PK parameters were derived. Geometric mean ratios (GMR) and 90% confidence intervals (90%CI) for DIG C max and AUC inf were derived from linear mixed effects models.
Results. All subjects (69% male, aged 23-45 years) completed the study. DCV -+ ASV dosed with DIG resulted in a 77% increase in DIG C max and a 29% increase in AUC inf (Table) . Study drugs were well tolerated; all AEs were mild in intensity except 2 AEs of increased blood creatinine phosphokinase (1 moderate, 1 severe). No AEs were considered study drug-related and all resolved by study end. 
